These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32839263)

  • 21. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
    Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
    Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Imatinib in Paediatric CML - A Single Centre Study.
    Smeding C; Szydło A; Pieluszczak K; Grzeszkiewicz K; Pawelec K
    In Vivo; 2019; 33(3):869-875. PubMed ID: 31028210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
    Castagnetti F; Di Raimondo F; De Vivo A; Spitaleri A; Gugliotta G; Fabbiano F; Capodanno I; Mannina D; Salvucci M; Antolino A; Marasca R; Musso M; Crugnola M; Impera S; Trabacchi E; Musolino C; Cavazzini F; Mineo G; Tosi P; Tomaselli C; Rizzo M; Siragusa S; Fogli M; Ragionieri R; Zironi A; Soverini S; Martinelli G; Cavo M; Vigneri P; Stagno F; Rosti G; Baccarani M
    Am J Hematol; 2017 Jan; 92(1):82-87. PubMed ID: 27770583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
    Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
    Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status.
    Kenzik KM; Bhatia R; Bhatia S
    JAMA Oncol; 2020 Apr; 6(4):542-546. PubMed ID: 31999305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020].
    Wang HF; Zhang YL; Liu XL; Zhu HL; Liang R; Liu BC; Zhou L; Meng L; Li WM; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):535-542. PubMed ID: 34455739
    [No Abstract]   [Full Text] [Related]  

  • 28. Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
    Novo G; Di Lisi D; Bronte E; Macaione F; Accurso V; Badalamenti G; Rinaldi G; Siragusa S; Novo S; Russo A
    Oncology; 2020; 98(7):445-451. PubMed ID: 32348984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
    Front Immunol; 2018; 9():3152. PubMed ID: 30705677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.
    Crisan AM; Coriu D; Arion C; Colita A; Jardan C
    J Med Life; 2015; 8(4):502-8. PubMed ID: 26664479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
    Fujisawa S; Ueda Y; Usuki K; Kobayashi H; Kondo E; Doki N; Nakao T; Kanda Y; Kosugi N; Kosugi H; Kumagai T; Harada H; Shikami M; Maeda Y; Sakura T; Inokuchi K; Saito A; Nawa Y; Ogasawara M; Nishida J; Kondo T; Yoshida C; Kuroda H; Tabe Y; Maeda Y; Imajo K; Kojima K; Morita S; Komukai S; Kawaguchi A; Sakamoto J; Kimura S
    Int J Clin Oncol; 2019 Apr; 24(4):445-453. PubMed ID: 30421023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia.
    Szeto AH; Bucci T; Deal A; Zhu A; Ahmad M; Cass AS; Sketch MR; Kemper R; Zeidner JF; Foster MC; Muluneh B; Crona DJ
    Ann Pharmacother; 2022 Jul; 56(7):753-763. PubMed ID: 34541881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.
    Francis S; Lucas C; Lane S; Wang L; Watmough S; Knight K; Bell J; Kaleel-Rahman M; Lee E; O'Brien D; Butt NM; Sadik W; De Soysa L; Seale JR; Salim R; Clark RE
    Leuk Res; 2013 Jul; 37(7):752-8. PubMed ID: 23618689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effects of Tyrosine Kinase Inhibitors on the Th1 and Treg Cells of CML Patients].
    Dai JY; Yang X; Wei Q; Li H; Huang XB; Wang XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):25-32. PubMed ID: 30738443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and Monitoring of Chronic Myeloid Leukemia: Chiang Mai University Experience.
    Tantiworawit A; Kongjarern S; Rattarittamrong E; Lekawanvijit S; Bumroongkit K; Boonma N; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Norasetthada L
    Asian Pac J Cancer Prev; 2016; 17(4):2159-64. PubMed ID: 27221912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors.
    Karakulak UN; Aladag E; Hekimsoy V; Sahiner ML; Kaya EB; Ozer N; Aksu S; Demiroglu H; Goker H; Buyukasik Y; Ozcebe O; Sayinalp N; Haznedaroglu IC
    Cardiovasc Toxicol; 2021 Mar; 21(3):216-223. PubMed ID: 33068232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
    Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.